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A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant *Klebsiella pneumoniae* infections\
International Journal of Antimicrobial Agents.**Value of the Data**•The data contained in this dataset are useful because they could be employed in further studies to investigate treatment outcomes following antibiotic treatment in patients with CRKP infections.•The data contained in the present dataset are related to treatment outcomes (mortality, clinical and microbiological response) among antibiotic-treated CRKP-infected patients and has been obtained from multiple studies in different countries. Therefore, patients with infections caused by CRKP, and clinicians treating these patients can benefit from these data.•This dataset can be used to generate further insights by informing future trials that seek to examine antibiotic treatment choices for CRKP infections.•The method of data collection is systematic review and meta-analysis. Therefore, an additional value of the methods described and the data synthesized is that they can be useful for future systematic reviews and meta-analysis.

1. Data {#sec1}
=======

Based on the inclusion criteria, out of 1863 articles initially screened, fifty-five articles (54 studies) reporting treatment outcomes among antibiotic-treated CRKP-infected patients were included in the meta-analysis ([Fig. 1](#fig1){ref-type="fig"}). The included studies were of good quality as per their quality appraisal scores ([Table 1](#tbl1){ref-type="table"}) which were evaluated using the Newcastle-Ottawa scale (NOS) for nonrandomized trials included in meta-analyses \[[@bib1]\].Fig. 1Flow diagram of the systematic review process.Fig. 1Table 1Newcastle-Ottawa Scale for quality assessment of included studies.Table 1Article No.First author, yearCriteria for quality assessmentTotal quality scoreSelectionComparabilityOutcome/Exposure12341231Alexander, 2012 \[[@bib2]\]\*n.a\*\*n.a\*\*\*62Bergamasco, 2012 \[[@bib3]\]\*n.a\*\*n.a\*\*\*73Brizendine, 2015 \[[@bib4]\]\*\*\*\*\* \*\*\*\*94Capone, 2013 \[[@bib5]\]\*n.a\*\*n.a\*\*-55Cprek, 2016 \[[@bib6]\]\*n.a\*\*n.a\*\*\*66Daikos, 2009 \[[@bib7]\]\*\*\*\*\*\*\*\*\*97Daikos, 2014 \[[@bib8]\]\*n.a\*\*n.a\*\*\*68Dubrovskaya, 2013 \[[@bib9]\]\*n.a\*\*n.a\*\*\*69Gomez-Simmonds, 2016 \[[@bib10]\]\*n.a\*\*n.a\*\*\*610Ji, 2015 \[[@bib11]\]\*n.a\*\*n.a\*\*\*611Machuca, 2017 \[[@bib12]\]\*n.a\*\*n.a\*\*\*612Michalopoulos, 2010 \[[@bib13]\]\*n.a\*\*n.a\*\*\*613Mouloudi, 2010 \[[@bib14]\]\*\*\--\*\*\*\*n.a614Nguyen, 2010 \[[@bib15]\]\*n.a\*\*n.a\*\*\*615Qureshi, 2012 \[[@bib16]\]\*n.a\*\*n.a\*\*\*616Qureshi, 2014 \[[@bib17]\]\*\*\*\*\*\*\*\*\*917Sanchez-Romero, 2012 \[[@bib18]\]\*\*\*\*\*\*\*-\*818Satlin, 2011 \[[@bib19]\]\*n.a\*\*n.a\*\*\*619Souli, 2008 \[[@bib20]\]\*n.a\*\*n.a\*\*\*620Souli, 2010 \[[@bib21]\]\*n.a\*\*n.a\*\*\*621Souli, 2017 \[[@bib22]\]\*n.a\*\*n.a\*\*\*622Shields, 2016a \[[@bib23]\]\*n.a\*\*n.a\*\*\*623Trecarichi, 2016 \[[@bib24]\]\*\*\*\*\*\*\*\*\*924Tumbarello, 2012 \[[@bib25]\]\*n.a\*\*n.a\*\*\*625Tumbarello, 2015 \[[@bib26]\]\*n.a\*\*n.a\*\*\*626Vardakas, 2015 \[[@bib27]\]\*n.a\*\*n.a\*\*\*627Venugopalan, 2017 \[[@bib28]\]\*\*\*\*\*\*\*\*n.a828Weisenberg, 2009 \[[@bib29]\]\*n.a\*\*n.a\*-\*529Daikos, 2007 \[[@bib30]\]\*\*\--\*\*\*\*n.a630Maltezou, 2009 \[[@bib31]\]\*n.a\*\*n.a\*\*\*631Navarro-San, 2013 \[[@bib32]\]\*n.a\*\*n.a\*\*\*632Di Carlo, 2013 \[[@bib33]\]\*n.a\*\*n.a\*\*\*633Balandin, 2014 \[[@bib34]\]\*n.a\*\*n.a\*\*\*634Kontopidou, 2014 \[[@bib35]\]\*n.a\*\*n.a\*\*\*635McLaughlin, 2014 \[[@bib36]\]\*\*-\*\*\*\*\*n.a736Pontikis, 2014 \[[@bib37]\]\*n.a\*\*n.a\*\*\*637Mammina, 2010 \[[@bib38]\]\*n.a\*\*n.a\*\*\*638Oliva, 2017 \[[@bib39]\]\*n.a\*\*n.a\*\*\*639Gonzalez-Padilla, 2015 \[[@bib40]\]\*n.a\*\*n.a\*\*\*640Neuner, 2011 \[[@bib41]\]\*n.a\*\*n.a\*\*\*641Falagas, 2007 \[[@bib42]\]\*\*-\*\*\*\*\*n.a742Sbrana, 2013 \[[@bib43]\]\*n.a\*\*n.a\*\*\*643Papadimitriou-Olivgeris, 2017 \[[@bib44]\]\*\*-\*\*\*\*\*n.a744Falcone, 2016 \[[@bib45]\]\*n.a\*\*n.a\*\*\*645Liao, 2017 \[[@bib46]\]\*n.a\*\*n.a\*-\*546De Pascale, 2017 \[[@bib47]\]\*\*\--\*\*\*\*n.a647Freire, 2015 \[[@bib48]\]\*\*\*\*\*\*\*\*\*948Hussein, 2013 \[[@bib49]\]\*\*-\*\*\*\*\*n.a749Simkins, 2014 \[[@bib50]\]\*\*-\*\*\*\*\*n.a750Shields, 2016b \[[@bib51]\]\*n.a\*\*n.a\*\*\*651Russo, 2018 \[[@bib52]\]\*\*-\*\*\*\*\*n.a752Su, 2018 \[[@bib53]\]\*n.a\*\*n.a\*\*\*653Varotti, 2017 \[[@bib54]\]\*\*-\*\*\*\*\*n.a754Pouch, 2015 \[[@bib55]\]\*\*-\*\*\*\*\*n.a755Duani, 2018 \[[@bib56]\]\*\*-\*\*\*\*\*n.a7[^1]

1.1. Mortality {#sec1.1}
--------------

The data showed that the overall pooled mortality rate among the CRKP-infected patients treated with antibiotics was 37.2% (95% CI 33.1--41.4%; *I*^2^ = 76.8%) ([Fig. 2](#fig2){ref-type="fig"}). Sub-group analyses based on geographic region (North America: 30.4%, 95% CI 20.9--40.8%, *I*^2^ = 80.4%; other: 39.5%, 95% CI 35.1--44.1%, *I*^2^ = 74.7%), publication years (≤2012: 40.8%, 95% CI 31.4--50.6%; *I*^2^ = 67.2%; 2013--2018: 36.1%, 95% CI 31.5--40.8%, *I*^2^ = 79.8%) and study design (retrospective: 37.5%, 95% CI 32.6--42.5%, *I*^2^ = 79.1%: prospective: 35.4%, 95% CI 28.2--42.9%; *I*^2^ = 56.6%) did not result in significant reduction in heterogeneity levels for the pooled mortality rates. Moreover, funnel plot visualization showed no evidence of publication bias ([Fig. 3](#fig3){ref-type="fig"}).Fig. 2Pooled mortality rates following antibiotic treatment among CRKP-infected patients in the included studies.Fig. 2Fig. 3Funnel plot depicting reported mortality rates following antibiotic therapy across included studies.Fig. 3

Compared to combination therapy, monotherapy was associated with a higher likelihood of mortality (odds ratio \[OR\] 1.45, 95% CI 1.18--1.78; *I*^2^ = 0.0%) ([Fig. 4](#fig4){ref-type="fig"}). However, there were no significant differences in the likelihood of mortality between CRKP-infected patients treated with 2-drug and ≥3-drug combination regimens ([Fig. 5](#fig5){ref-type="fig"}) or between the combination containing and sparing regimens of carbapenems ([Fig. 6](#fig6){ref-type="fig"}), polymyxins ([Fig. 7](#fig7){ref-type="fig"}), aminoglycosides ([Fig. 8](#fig8){ref-type="fig"}) and tigecycline ([Fig. 9](#fig9){ref-type="fig"}). Moreover, there were no significant differences in the likelihood of mortality between the various monotherapies ([Table 2](#tbl2){ref-type="table"}). The comparison of the mortality outcomes across the various antibiotic combination regimens did not change when the analysis was restricted to 14- and 30-day mortality ([Table 3](#tbl3){ref-type="table"}).Fig. 4Comparison of mortality between CRKP-infected patients treated with monotherapy and combination therapies.Fig. 4Fig. 5Comparison of mortality between CRKP-infected patients treated with ≥3-drug and those on 2-drug combination therapies.Fig. 5Fig. 6Comparison of mortality between CRKP-infected patients treated with carbapenem-containing and carbapenem-sparing combination therapies.Fig. 6Fig. 7Comparison of mortality between CRKP-infected patients treated with polymyxin-containing and polymyxin-sparing combination therapies.Fig. 7Fig. 8Comparison of mortality between CRKP-infected patients treated with aminoglycoside-containing and aminoglycoside-sparing combination therapies.Fig. 8Fig. 9Comparison of mortality between CRKP-infected patients treated with tigecycline-containing and tigecycline-sparing combination therapies.Fig. 9Table 2Comparison of mortality, microbiological and clinical response rate according to various antibiotic monotherapies.Table 2OutcomeNo. of studies pooledNo. of patientsOdds Ratio (OR) (95% CI)Heterogeneity of included studiesMortality Carbapenem vs polymyxin7980.83 (0.29--2.40)18.3%, p = 0.290 Carbapenem vs aminoglycoside101101.83 (0.67--4.97)11.3%, p = 0.339 Carbapenem vs tigecycline81031.43 (0.56--3.69)0.0%, 0.540 Polymyxin vs aminoglycoside113771.10 (0.70--1.71)0.0%, p = 0.557 Polymyxin vs tigecycline114220.84 (0.56--1.25)0.0%, p = 0.788 Aminoglycoside vs tigecycline111880.53 (0.27--1.04)0.0%, p = 0.980Clinical response Carbapenem vs polymyxinNo pooled data (1 datapoint)------ Carbapenem vs aminoglycoside3190.75 (0.08--7.08)0.0%, p = 0.592 Carbapenem vs tigecycline3270.92 (0.14--5.91)0.0%, p-0.554 Polymyxin vs aminoglycoside2501.10 (0.13--9.61)28.7%, p = 0.236 Polymyxin vs tigecycline4692.27 (0.46--11.27)0.0%, p = 0.564 Aminoglycoside vs tigecycline3562.58 (0.79--8.41)0.0%, p = 0.997Microbiological response Carbapenem vs polymyxinNo pooled data (0 datapoint)------ Carbapenem vs aminoglycosideNo pooled data (1 datapoint)------ Carbapenem vs tigecyclineNo pooled data (1 datapoint)------ Polymyxin vs aminoglycosideNo pooled data (1 datapoint)------ Polymyxin vs tigecycline2502.76 (0.87--8.68)0.0%, p = 0.344 Aminoglycoside vs tigecycline2653.00 (0.60--15.1)0.0%, p = 0.580Table 3Sub-group analyses of 14-day and 30-day mortality following specific antibiotic therapies among CRKP-infected patients.Table 3MortalityNo. of studies pooledNo. of patientsOdds Ratio (OR) (95% CI)Heterogeneity of included studiesBy 14-day Monotherapy vs combination8935**1.42 (1.06**--**1.90); p** = **0.020**I^2^ = 0.0%; p = 0.907 2-drug vs ≥ 3-drug combination84900.91 (0.59--1.41); p = 0.674I^2^ = 0.0%; p = 0.844 Carbapenem-containing vs carbapenem-sparing4651.39 (0.31--6.16); p = 0.664I^2^ = 0.0%; p = 0.700 Polymyxin-containing vs polymyxin-sparing51141.45 (0.50--4.16); p = 0.491I^2^ = 0.0%; p = 0.531 Aminoglycoside-containing vs aminoglycoside-sparing61170.46 (0.17--1.24); p = 0.125I^2^ = 0.0%; p = 0.504 Tigecycline-containing vs tigecycline-sparing51061.70 (0.60--4.78); p = 0.315I^2^ = 0.0%; p = 0.890By 28-day or 30-day Monotherapy vs combination14763**1.54 (1.09**--**2.17); p** = **0.015**I^2^ = 1.2%; p = 0.436 2-drug vs ≥ 3-drug combination135550.91 (0.59--1.42); p = 0.684I^2^ = 9.2%; p = 0.353 Carbapenem-containing vs carbapenem-sparing114700.65 (0.37--1.12); p = 0.123I^2^ = 14.2%; p = 0.309 Polymyxin-containing vs polymyxin-sparing124571.33 (0.64--2.75); p = 0.446I^2^ = 53.8%; p = 0.014 Aminoglycoside-containing vs aminoglycoside-sparing135450.99 (0.58--1.67); p = 0.956I^2^ = 27.0%; p = 0.172 Tigecycline-containing vs tigecycline-sparing115071.09 (0.48--2.45); p = 0.844I^2^ = 56.1%; p = 0.012[^2]

1.2. Clinical response {#sec1.2}
----------------------

The data showed that the overall pooled clinical response rate among the CRKP-infected patients treated with antibiotics was 69.0% (95% CI 60.1--78.2%; *I*^2^ = 82.8%) ([Fig. 10](#fig10){ref-type="fig"}). Sub-group analyses based on geographic region (North America: 64.9%, 95% CI 50.1--78.5%, *I*^2^ = 80.4; other: 72.4%, 95% CI 60.0--83.4%; *I*^2^ = 85.4%), publication years (≤2012: 73.9%, 95% CI 57.1--88.0%; *I*^2^ = 82.5%; 2013--2018: 66.3%, 95% CI 54.9--76.9%, *I*^2^ = 83.6%) and study design (retrospective: 67.1%, 95% CI 55.5--77.7%, *I*^2^ = 84.4%: prospective: 79.7%, 95% CI 63.2--92.6%; *I*^2^ = 59.4%) did not result in significant reduction in heterogeneity levels for the pooled clinical response rate. Moreover, direct observation of the funnel plot did not show any obvious evidence of publication bias ([Fig. 11](#fig11){ref-type="fig"}).Fig. 10Pooled clinical response rates following antibiotic treatment among CRKP-infected patients in the included studies.Fig. 10Fig. 11Funnel plot depicting reported clinical response rates following antibiotic therapy across included studies.Fig. 11

There was no significant difference in the clinical response rate between monotherapy and combination regimens ([Fig. 12](#fig12){ref-type="fig"}), nor between 2-drug and ≥3-drug combination regimens ([Fig. 13](#fig13){ref-type="fig"}). Furthermore, no significant differences were noted in the pooled clinical response between combination containing and sparing regimens of carbapenems ([Fig. 14](#fig14){ref-type="fig"}), polymyxins ([Fig. 15](#fig15){ref-type="fig"}), aminoglycosides ([Fig. 16](#fig16){ref-type="fig"}) and tigecycline ([Fig. 17](#fig17){ref-type="fig"}). Moreover, there were no significant differences in the likelihood of clinical response between the various monotherapies ([Table 2](#tbl2){ref-type="table"}).Fig. 12Comparison of clinical response between CRKP-infected patients treated with monotherapy and combination therapies.Fig. 12Fig. 13Comparison of clinical response between CRKP-infected patients treated with ≥3-drug and those on 2-drug combination therapies.Fig. 13Fig. 14Comparison of clinical response between CRKP-infected patients treated with carbapenem-containing and carbapenem-sparing combination therapies.Fig. 14Fig. 15Comparison of clinical response between CRKP-infected patients treated with polymyxin-containing and polymyxin-sparing combination therapies.Fig. 15Fig. 16Comparison of clinical response between CRKP-infected patients treated with aminoglycoside-containing and aminoglycoside-sparing combination therapies.Fig. 16Fig. 17Comparison of clinical response between CRKP-infected patients treated with tigecycline-containing and tigecycline-sparing combination therapies.Fig. 17

1.3. Microbiological response {#sec1.3}
-----------------------------

The data showed that the overall pooled microbiological response rate among the CRKP-infected patients treated with antibiotics was 63.7% (95% CI 53.7--74.1%; *I*^2^ = 82.1%) ([Fig. 18](#fig18){ref-type="fig"}). Sub-group analyses based on geographic region (North America: 71.6%, 95% CI 63.6--79.1%, *I*^2^ = 48.7%; other: 53.9%, 95% CI 34.5--72.7%, *I*^2^ = 86.7%), publication years (≤2012: 67.8%, 95% CI 49.1--84.2%; *I*^2^ = 82.6%; 2013--2018: 62.2%, 95% CI 49.3--74.4%, *I*^2^ = 80.9%) and study design (retrospective: 63.2%, 95% CI 51.6--74.1%, *I*^2^ = 81.9%; prospective: 78.8%, 95% CI 60.6--92.9%; *I*^2^ = 68.0%) did not result in significant reduction in heterogeneity levels for the pooled microbiological response rate. Moreover, as per the funnel plot visualization, there was no obvious presence of publication bias ([Fig. 19](#fig19){ref-type="fig"}).Fig. 18Pooled microbiological response rates following antibiotic treatment among CRKP-infected patients in the included studies.Fig. 18Fig. 19Funnel plot depicting reported microbiological response rates following antibiotic therapy across included studies.Fig. 19

There was no significant difference in the microbiological response rate between monotherapy and combination regimens ([Fig. 20](#fig20){ref-type="fig"}), nor between 2-drug and ≥3-drug combination regimens ([Fig. 21](#fig21){ref-type="fig"}). Furthermore, no significant differences were noted in the pooled microbiological response between combination containing and sparing regimens of carbapenems ([Fig. 22](#fig22){ref-type="fig"}), polymyxins ([Fig. 23](#fig23){ref-type="fig"}), aminoglycosides ([Fig. 24](#fig24){ref-type="fig"}) and tigecycline ([Fig. 25](#fig25){ref-type="fig"}). Moreover, there were no significant differences in the likelihood of clinical response between the various monotherapies ([Table 2](#tbl2){ref-type="table"}).Fig. 20Comparison of microbiological response between CRKP-infected patients treated with monotherapy and combination therapies.Fig. 20Fig. 21Comparison of microbiological response between CRKP-infected patients treated with ≥3-drug and those on 2-drug combination therapies.Fig. 21Fig. 22Comparison of microbiological response between CRKP-infected patients treated with carbapenem-containing and carbapenem-sparing combination therapies.Fig. 22Fig. 23Comparison of microbiological response between CRKP-infected patients treated with polymyxin-containing and polymyxin-sparing combination therapies.Fig. 23Fig. 24Comparison of microbiological response between CRKP-infected patients treated with aminoglycoside-containing and aminoglycoside-sparing combination therapies.Fig. 24Fig. 25Comparison of microbiological response between CRKP-infected patients treated with tigecycline-containing and tigecycline-sparing combination therapies.Fig. 25

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Search strategy {#sec2.1}
--------------------

In this article, treatment outcomes (mortality, clinical and microbiological response) among antibiotic-treated CRKP-infected patients were reviewed based on published literature. More specifically, a thorough systematic literature search was conducted in Medline, EMBASE, the Cochrane Central Register of Controlled Trials, and the International Pharmaceutical Abstracts databases from their inception to December 26 2018 using the using search terms such as *Klebsiella pneumoniae*, antibiotic therapy and carbapenem resistance. The full search strategy is presented in [Table 4](#tbl4){ref-type="table"}. The database searches were also supplemented by manual reference screening of the included articles.Table 4Search strategy for Ovid Medline which was adapted for other databases.Table 41(Klebsiella adj2 pneumoniae).mp2*Klebsiella pneumoniae*.mp. or exp *Klebsiella pneumoniae*/3exp Enterobacteriaceae/or Enterobacteriaceae.mp.4or/1-35(antibiotic adj2 therap\*).mp.6(antibiot\* adj2 treatment).mp.7(antibacterial adj2 agent\*).mp.8(antibacterial adj2 therap\*).mp.9antibacterial agent.mp.10(antibacterial\* adj2 activit\*).mp.11or/5-1012(carbapenem adj2 resist\*).mp.13(carbapenemase adj2 producing).mp.14carbapenem resistance.mp.15KPC.mp16(Metallo adj2 Lactamase).mp.17Metallo beta lactamase.mp.18VIM-producing.mp.19(VIM adj2 produc\*).mp.20IMP-producing.mp.21(IMP adj2 produc\*).mp.22NDM-producing.mp.23(NDM adj2 produc\*).mp.24OXA.mp.25CRE.mp.26Carbapenem-resistant.mp.27or/12-26284 and 11 and 2729limit 28 to English language

3. Methodological quality assessment {#sec3}
====================================

All studies that met the selection criteria were assessed for quality via the Newcastle-Ottawa scale (NOS) for nonrandomized trials included in meta-analyses \[[@bib1]\]. Studies achieving a NOS score of ≥5 were deemed to be of sufficient quality for inclusion in the review.

3.1. Inclusion and exclusion criteria {#sec3.1}
-------------------------------------

All studies addressing treatment outcomes for patients with infections caused by CRKP who received antibiotic therapy were eligible for inclusion. Studies involving both infected and colonized patients were included if the treatment outcomes of the infected patients could be separately extracted. Studies were excluded if they were based upon case reports or case series of \<10 patients, focused on children or were *in vitro* or animal studies. Conference abstracts and meeting reports were also excluded.

3.2. Data extraction {#sec3.2}
--------------------

A pre-designed data extraction form was used to collect relevant data. The extracted information included study details (first author, publication year, sample size, period, design, and country), population characteristics (gender distribution, mean age, site of infection etc.), antibiotic susceptibility testing (AST), details of antibiotic regimen, treatment outcomes (mortality, clinical response, and microbiological response) and any reported adverse events. All-cause mortality evaluated at end of patient follow-up was the primary outcome measurement. We additionally extracted data specifically for 14-day and 30-day mortality. The secondary outcomes were clinical response, microbiological response and adverse events. Due to the lack of standard and uniform criteria for the assessment and reporting of clinical response and microbiological response we adopted the definitions as employed in individual studies. The articles' screening and selection process was conducted according to the PRISMA Guidelines \[[@bib57]\].

3.3. Data analysis {#sec3.3}
------------------

The overall all-cause mortality, clinical response and microbiological response rates were determined via meta-analysis proportion. The meta-analysis was performed using the Freeman-Tukey double arcsine transformed proportions to stabilize the variance \[[@bib58]\]. A random-effects (DerSimonian and Laird) model was used in the meta-analysis due to the anticipated heterogeneity across studies. For the comparative assessment of treatment outcomes following specific antibiotic therapies, the effect measure was expressed as odds ratios (ORs). Cochran\'s Q test and the *Ι*^2^ statistic were used to quantify the presence of statistical heterogeneity \[[@bib59]\]. *I*^2^ values of 25%, 50%, and 75% were considered to be low, moderate, and high degrees of heterogeneity, respectively. To examine the potential sources of heterogeneity in the pooled mortality, clinical and microbiological response rates, we performed subgroup analyses based on the following characteristics: geographic region (North America *vs.* other), publication years (≤2012 *vs.* 2013--2018) and study design (prospective *vs.* retrospective). The presence of publication bias was assessed by direct observation of funnel plots and quantified with Egger\'s regression test \[[@bib60]\]. To examine the robustness of our pooled estimates, leave-one-out sensitivity analyses were performed. A study was considered influential if the pooled estimate without it was outside the 95% CIs of the overall pooled estimate. All analyses were performed using Stata 15/IC (StataCorp LP, College Station, Texas, USA). P-value \<0.05 was considered as statistically significant.
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[^1]: \*Fulfillment of items within a section; n.a, not applicable.

[^2]: The bold values represent the significant results.
